Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 214,041,663 papers from all fields of science
Search
Sign In
Create Free Account
GDC 0941
Known as:
GDC-0941
, GDC0941
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Abstract 798: Androgen receptor, PI3K/mTOR and PSMA: Exploring and exploiting the interplay between therapeutic targets in prostate cancer
J. Murga
,
W. Magargal
,
S. Moorji
,
V. DiPippo
,
W. Olson
2014
Corpus ID: 70739864
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Introduction: Androgen receptor (AR), the PI3K/mTOR…
Expand
2013
2013
Single cell network profiling assay in bladder cancer
T. Covey
,
M. Vira
,
+8 authors
A. Cesano
Cytometry Part A
2013
Corpus ID: 39869293
The aim of this study was to assess the feasibility of applying the single cell network profiling (SCNP) assay to the examination…
Expand
2013
2013
Abstract S4-04: Overcoming resistance to PI3K inhibitors in PIK3CA mutant breast cancer using CDK4/6 inhibition: Results from a combinatorial drug screen
S. Vora
,
Nayoon Kim
,
+10 authors
J. Engelman
2013
Corpus ID: 72221171
Various components of the phosphatidylinositol 3-kinase (PI3K) pathway are deregulated across a spectrum of human cancers…
Expand
2013
2013
Abstract 5632: MEK inhibition leads to elevated HER3:PI3K in EGFR or HER2 driven cancer through feedback induction of HER1:3 and HER2:3 dimers.
N. Hoe
,
M. Mateling
,
+7 authors
Sharat Singh
2013
Corpus ID: 57156782
In wide range of human cancer, the phosphoinositide 3-kinase (PI3K)/AKT and RAF/MEK/ERK signaling pathways are activated…
Expand
2013
2013
Abstract 3395: BCR-Abl independent, Abl-TKI-therapy-resistant CML cells show enhanced sensitivity to GDC0941.
Marie-Claire Wagle
,
M. Wongchenko
,
+5 authors
Yibing Yan
2013
Corpus ID: 74812169
2012
2012
Cancer Therapy: Preclinical GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast CancerModels by Increasing Cell Death In Vitro and In Vivo
J. Wallin
,
Jane Guan
,
+7 authors
D. Sampath
2012
Corpus ID: 9884025
Purpose: Docetaxel is a front-line standard-of-care chemotherapeutic drug for the treatment of breast cancer. Phosphoinositide 3…
Expand
2012
2012
Combined Blockade of PI3K/AKT and EGFR/HER3 Enhances Anti-Tumor Activity in Triple Negative Breast Cancer
Jessica J. Tao
,
P. Ip
,
+9 authors
J. Baselga
2012
Corpus ID: 220696992
2012
2012
Abstract 3737: The PI3K/mTOR inhibitor PWT33597 regresses 786-0 renal xenografts
M. O’Farrell
,
R. Ventura
,
A. Tai
,
D. J. Matthews
2012
Corpus ID: 76407931
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL PWT33597 is a balanced dual inhibitor of…
Expand
2012
2012
Abstract P6-04-11: Combination of PI3K-AKT-mTOR and MEK-ERK pathway inhibitors overcome acquired resistance to letrozole in ER+ breast cancer models
P. De
,
Y. Sun
,
L. Friedman
,
S. Chen
,
N. Dey
,
B. Leyland-Jones
2012
Corpus ID: 72194688
Background: Approximately 60–70% of breast cancers (BC) express estrogen receptor (ERα) and/or progesterone receptor (PR), the…
Expand
2010
2010
Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC…
I. Krop
,
A. Wolff
,
+7 authors
A. Storniolo
2010
Corpus ID: 76089939
Background: Aberrant activation of the PI3K pathway has been hypothesized to reduce the efficacy of trastuzumab-based therapy in…
Expand